Travere Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M |
| Cost of revenue | $10.3M | $7.7M | $11.4M | $4.4M | $3.8M |
| Selling, general & administrative | $337.2M | $264.1M | $265.5M | $197.5M | $126.3M |
| Research and development | $206.0M | $217.5M | $245.0M | $7.5M | $201.2M |
| Operating income | -$62.8M | -$323.8M | -$388.1M | -$319.8M | -$199.4M |
| Interest expense | $10.7M | $11.2M | $11.3M | $11.0M | $19.7M |
| Pretax income | -$49.3M | -$320.5M | -$376.1M | -$331.2M | -$216.9M |
| Income tax expense | $988,000 | $120,000 | $223,000 | $313,000 | $409,000 |
| Net income | -$25.5M | -$321.5M | -$111.4M | -$278.5M | -$180.1M |
| Balance Sheet | |||||
| Cash and equivalents | $93.0M | $58.5M | $58.2M | $61.7M | $165.8M |
| Current assets | $437.6M | $416.7M | $616.8M | $486.4M | $582.8M |
| Total assets | $605.2M | $594.1M | $788.9M | $672.6M | $776.6M |
| Current liabilities | $159.9M | $200.8M | $177.9M | $142.2M | $124.1M |
| Total liabilities | $490.4M | $535.0M | $588.1M | $629.7M | $474.5M |
| Stockholders' equity | $114.8M | $59.1M | $200.8M | $42.9M | $302.1M |
| Cash Flow Statement | |||||
| Cash from operations | $37.8M | -$237.5M | -$280.0M | -$186.3M | -$14.8M |
| Depreciation and amortization | $60.7M | $43.6M | $38.5M | $20.7M | $12.7M |
| Stock-based compensation | $44.9M | $36.9M | $44.2M | $38.1M | $29.6M |
| Capital expenditure | — | — | $668,000 | $191,000 | $5.1M |
| Free cash flow | — | — | -$280.7M | -$186.5M | -$19.9M |
| Impairments | $0 | $1.2M | $0 | $0 | $0 |
Shares outstanding 93.0M · Free float 92.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.